CARLSBAD, Calif., Jan. 19, 2022 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (Nasdaq: IONS) today announced two
appointments that strengthen its leadership team and further
position it to become a leading, fully integrated biotechnology
company. Joseph T. Baroldi will assume the role of
executive vice president and chief business officer, effective
Jan. 31, 2022. He will serve as a
member of Ionis' executive leadership team and report to
Brett P. Monia, Ph.D., Ionis' chief
executive officer. In his role, Mr. Baroldi will provide strategic
guidance for and lead Ionis' business development and alliance
management activities. The company also appointed Eric P. Bastings,
M.D., as vice president, development strategy. Dr. Bastings will
draw on his extensive experience, including as the former deputy
director of the Office of Neuroscience at the U.S. Food and Drug
Administration (FDA), to provide senior clinical and regulatory
leadership in support of Ionis' goal to bring transformational
medicines to the market. He will report to Richard S. Geary, Ph.D., Ionis' executive vice
president and chief development officer.
"I'm excited to welcome Mr. Baroldi and Dr. Bastings to Ionis at
this pivotal time. They both bring extensive experience that will
be instrumental as we continue our efforts to maximize value for
patients and shareholders," said Dr. Monia. "Mr. Baroldi's strong
background in business and science, combined with his familiarity
with Ionis, ensure that he can immediately contribute to
strengthening our partnerships and further advancing Ionis'
technology through strategic business transactions. Dr. Bastings'
deep experience with clinical development and regulatory process
will be invaluable as we advance key mid- and late-stage programs,
including those in our industry-leading neurology pipeline."
Mr. Baroldi has more than 20 years of industry experience and
joins Ionis from Avidity Biosciences, where he served as chief
operating officer, playing an integral role in their initial public
offering and building their team over the last two years.
Previously, he was vice president, business development at Ionis,
where he held several roles of increasing responsibility over 10
years. At Ionis, he executed on strategic transactions that
resulted in the creation of significant value for the company.
Before that Mr. Baroldi held positions in strategic planning and
scientific research.
Mr. Baroldi holds an M.B.A. from the Rady School of Management
at the University of California-San
Diego. He received his B.S. in Biological Sciences from the
University of California-Irvine.
Dr. Bastings recently retired from the FDA after a distinguished
career of more than 20 years. In his most recent position at the
agency, Dr. Bastings provided strategic and clinical oversight of
five review divisions and led scientific and regulatory activities,
including the evaluation of the design of human trials supporting
development programs for investigational new drugs across all
neuroscience therapeutic areas, as well as the evaluation of the
safety and effectiveness of drugs across all neuroscience
therapeutic areas (NDAs, BLAs, and supplements).
Dr. Bastings received his medical degree from the University of
Liege in Belgium, where he also
completed his neurology residency.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been the leader in
RNA-targeted therapy, pioneering new markets and changing standards
of care with its novel antisense technology. Ionis currently has
three marketed medicines and a premier late-stage pipeline
highlighted by industry-leading neurological and cardiometabolic
franchises. Our scientific innovation began and continues with the
knowledge that sick people depend on us, which fuels our vision of
becoming one of the most successful biotechnology companies.
To learn more about Ionis visit www.ionispharma.com and follow
us on Twitter @ionispharma.
Ionis' Forward-looking Statements
This press release includes forward-looking statements regarding
Ionis' business and the therapeutic and commercial potential of
Ionis' technologies and other products in development. Any
statement describing Ionis' goals, expectations, financial or other
projections, intentions or beliefs is a forward-looking statement
and should be considered an at-risk statement. Such statements are
subject to certain risks and uncertainties, including those related
to the impact COVID-19 could have on our business, and including
but not limited to those related to our commercial products and the
medicines in our pipeline, and particularly those inherent in the
process of discovering, developing and commercializing medicines
that are safe and effective for use as human therapeutics, and in
the endeavor of building a business around such medicines. Ionis'
forward-looking statements also involve assumptions that, if they
never materialize or prove correct, could cause its results to
differ materially from those expressed or implied by such
forward-looking statements.
Although Ionis' forward-looking statements reflect the good
faith judgment of its management, these statements are based only
on facts and factors currently known by Ionis. As a result, you are
cautioned not to rely on these forward-looking statements. These
and other risks concerning Ionis' programs are described in
additional detail in Ionis' annual report on Form 10-K for the year
ended December 31, 2020, and the most
recent Form 10-Q quarterly filing, which are on file with the SEC.
Copies of these and other documents are available from the
Company.
In this press release, unless the context requires otherwise,
"Ionis," "Company," "we," "our," and "us" refers to Ionis
Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals® is a trademark of Ionis Pharmaceuticals,
Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ionis-strengthens-leadership-team-with-appointments-of-joseph-baroldi-as-chief-business-officer-and-eric-bastings-md-as-vice-president-development-strategy-301463392.html
SOURCE Ionis Pharmaceuticals, Inc.